The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo

Monte Willis, Amro Ilaiwy, Megan D. Montgomery, Paul C. Simpson, Brian C. Jensen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Alpha-1-adrenergic receptors (α1-ARs) are G-protein coupled receptors (GPCRs) with three highly homologous subtypes (α1A, α1B, and α1D). Of these three subtypes, only the α1A and α1B are expressed in the heart. Multiple pre-clinical models of heart injury demonstrate cardioprotective roles for the α1A. Non-selective α1-AR activation promotes glycolysis in the heart, but the functional α1-AR subtype and broader metabolic effects have not been studied. Objectives: Given the high metabolic demands of the heart and previous evidence indicating benefit from α1A activation, we chose to investigate the effects of α1A activation on the cardiac metabolome in vivo. Methods: Mice were treated for 1 week with a low, subpressor dose of A61603, a highly selective and potent α1A agonist. Cardiac tissue and serum were analyzed using a non-targeted metabolomics approach. Results: We identified previously unrecognized metabolic responses to α1A activation, most notably broad reduction in the abundance of polyunsaturated fatty acids (PUFAs) and endocannabinoids (ECs). Conclusion: Given the well characterized roles of PUFAs and ECs in inflammatory pathways, these findings suggest a possible role for cardiac α1A-ARs in the regulation of inflammation and may offer novel insight into the mechanisms underlying the cardioprotective benefit of selective pharmacologic α1A activation.

Original languageEnglish (US)
Article number155
JournalMetabolomics
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

A 61603
Adrenergic alpha-1 Receptors
Adrenergic alpha-Agonists
Endocannabinoids
Adrenergic Agonists
Metabolites
Unsaturated Fatty Acids
Chemical activation
Inflammation
Adrenergic Receptors
Heart Injuries
Metabolomics
Metabolome
Glycolysis
G-Protein-Coupled Receptors
Serum
Tissue

Keywords

  • Agonist
  • Alpha-1A adrenergic receptor
  • Anti-inflammatory
  • Arachidonic acid
  • Endocannabinoid
  • Fatty acid elongation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Clinical Biochemistry

Cite this

The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo. / Willis, Monte; Ilaiwy, Amro; Montgomery, Megan D.; Simpson, Paul C.; Jensen, Brian C.

In: Metabolomics, Vol. 12, No. 10, 155, 01.10.2016.

Research output: Contribution to journalArticle

@article{09e805660ba64ebca1d3cfe034c70ac9,
title = "The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo",
abstract = "Introduction: Alpha-1-adrenergic receptors (α1-ARs) are G-protein coupled receptors (GPCRs) with three highly homologous subtypes (α1A, α1B, and α1D). Of these three subtypes, only the α1A and α1B are expressed in the heart. Multiple pre-clinical models of heart injury demonstrate cardioprotective roles for the α1A. Non-selective α1-AR activation promotes glycolysis in the heart, but the functional α1-AR subtype and broader metabolic effects have not been studied. Objectives: Given the high metabolic demands of the heart and previous evidence indicating benefit from α1A activation, we chose to investigate the effects of α1A activation on the cardiac metabolome in vivo. Methods: Mice were treated for 1 week with a low, subpressor dose of A61603, a highly selective and potent α1A agonist. Cardiac tissue and serum were analyzed using a non-targeted metabolomics approach. Results: We identified previously unrecognized metabolic responses to α1A activation, most notably broad reduction in the abundance of polyunsaturated fatty acids (PUFAs) and endocannabinoids (ECs). Conclusion: Given the well characterized roles of PUFAs and ECs in inflammatory pathways, these findings suggest a possible role for cardiac α1A-ARs in the regulation of inflammation and may offer novel insight into the mechanisms underlying the cardioprotective benefit of selective pharmacologic α1A activation.",
keywords = "Agonist, Alpha-1A adrenergic receptor, Anti-inflammatory, Arachidonic acid, Endocannabinoid, Fatty acid elongation",
author = "Monte Willis and Amro Ilaiwy and Montgomery, {Megan D.} and Simpson, {Paul C.} and Jensen, {Brian C.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s11306-016-1097-3",
language = "English (US)",
volume = "12",
journal = "Metabolomics",
issn = "1573-3882",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo

AU - Willis, Monte

AU - Ilaiwy, Amro

AU - Montgomery, Megan D.

AU - Simpson, Paul C.

AU - Jensen, Brian C.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction: Alpha-1-adrenergic receptors (α1-ARs) are G-protein coupled receptors (GPCRs) with three highly homologous subtypes (α1A, α1B, and α1D). Of these three subtypes, only the α1A and α1B are expressed in the heart. Multiple pre-clinical models of heart injury demonstrate cardioprotective roles for the α1A. Non-selective α1-AR activation promotes glycolysis in the heart, but the functional α1-AR subtype and broader metabolic effects have not been studied. Objectives: Given the high metabolic demands of the heart and previous evidence indicating benefit from α1A activation, we chose to investigate the effects of α1A activation on the cardiac metabolome in vivo. Methods: Mice were treated for 1 week with a low, subpressor dose of A61603, a highly selective and potent α1A agonist. Cardiac tissue and serum were analyzed using a non-targeted metabolomics approach. Results: We identified previously unrecognized metabolic responses to α1A activation, most notably broad reduction in the abundance of polyunsaturated fatty acids (PUFAs) and endocannabinoids (ECs). Conclusion: Given the well characterized roles of PUFAs and ECs in inflammatory pathways, these findings suggest a possible role for cardiac α1A-ARs in the regulation of inflammation and may offer novel insight into the mechanisms underlying the cardioprotective benefit of selective pharmacologic α1A activation.

AB - Introduction: Alpha-1-adrenergic receptors (α1-ARs) are G-protein coupled receptors (GPCRs) with three highly homologous subtypes (α1A, α1B, and α1D). Of these three subtypes, only the α1A and α1B are expressed in the heart. Multiple pre-clinical models of heart injury demonstrate cardioprotective roles for the α1A. Non-selective α1-AR activation promotes glycolysis in the heart, but the functional α1-AR subtype and broader metabolic effects have not been studied. Objectives: Given the high metabolic demands of the heart and previous evidence indicating benefit from α1A activation, we chose to investigate the effects of α1A activation on the cardiac metabolome in vivo. Methods: Mice were treated for 1 week with a low, subpressor dose of A61603, a highly selective and potent α1A agonist. Cardiac tissue and serum were analyzed using a non-targeted metabolomics approach. Results: We identified previously unrecognized metabolic responses to α1A activation, most notably broad reduction in the abundance of polyunsaturated fatty acids (PUFAs) and endocannabinoids (ECs). Conclusion: Given the well characterized roles of PUFAs and ECs in inflammatory pathways, these findings suggest a possible role for cardiac α1A-ARs in the regulation of inflammation and may offer novel insight into the mechanisms underlying the cardioprotective benefit of selective pharmacologic α1A activation.

KW - Agonist

KW - Alpha-1A adrenergic receptor

KW - Anti-inflammatory

KW - Arachidonic acid

KW - Endocannabinoid

KW - Fatty acid elongation

UR - http://www.scopus.com/inward/record.url?scp=84987915634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987915634&partnerID=8YFLogxK

U2 - 10.1007/s11306-016-1097-3

DO - 10.1007/s11306-016-1097-3

M3 - Article

AN - SCOPUS:84987915634

VL - 12

JO - Metabolomics

JF - Metabolomics

SN - 1573-3882

IS - 10

M1 - 155

ER -